Escudero-Lourdes GV, Figueroa-Vallejo FJ, Bisset-Mandeville P, Rodríguez-Martínez M, Hernández-Sierra F

Language: Spanish
References: 26
Page: 183-188
PDF size: 245.69 Kb.

ABSTRACT

Introduction: In Mexico, it is estimated that eight to 10% of births are preterm newborns. Achieving adequate growth and development are one of the challenges of caring for prematures, which is why supplementation of nutrients, such as levocarnitine, is recommended. Objective: To assess the efficacy of oral levocarnitine in weight gain of prematures, compared with placebo. Material and methods: A randomized, double-blind controlled trial, compared with placebo, was carried out in a General Hospital, San Luis Potosí, Mexico. Patients weighing less than 1.8 kg were included, who had conditions to receive enteral feeding. The experimental group received 100 mg/kg/day of levocarnitine, and the control group 5% glucose solution. Weight gain (grams) at 7, 14 and 21 days, as well as length of hospital stay, were evaluated. Statistical analysis was performed with Chi-square and Student’s t. Results: There were 32 prematures in the levocarnitine group and 28 in the placebo group. When analyzing the weight, the experimental group had an average weight gain of 167.8 g ± 54.97, 203.5 g ± 65.05 and 202.1 g ± 57.58, in the three weekly measurements. Which was higher (p <0.05) than in the control group: 143.4 g ± 60.32, 174.5 g ± 52.86 and 151 g ± 44.58, respectively. In addition, the experimental group had fewer days of hospitalization, 15.5 ± 7.1 vs 18.1 ± 8.6. Conclusion: In preterm newborns without complications, the administration of oral levocarnitine is effective in improving weight gain and probably in reducing hospital stay.

REFERENCES

1. Organización Mundial de la Salud [Internet]. Nacimientos prematuros. Suiza: OMS; c2019. 19 febrero 2019 [citado 18 jun 2019]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/preterm-birth.

2. Gómez-Gómez M, Danglot-Banck C, Aceves-Gómez M. Clasificación de los niños recién nacidos. Rev Mex Pediatr. 2012; 79(1): 32-39.

3. Villanueva LA, Contreras AK, Pichardo M, Rosales J. Perfil epidemiológico del parto prematuro. Ginecol Obstet Mex. 2008; 76(9): 542-548.

4. IMSS. Sistema de información de morbilidad. 2006. Delegación San Luis Potosí S.L.P. H.G.Z. 1.

5. Goldenberg RL. The management of preterm labor. Obstet Gynecol. 2002; 100(5Pt1): 1020-1037.

6. Martínez y Martínez R. La salud del niño y el adolescente. 8a ed. México: Manual Moderno; 2017.

7. Mendoza LA, Claros DI, Mendoza LI, Arias MD, Peñaranda CB. Epidemiología de la prematuridad, sus determinantes y prevención del parto prematuro. Rev Chil Obstet Ginecol. 2016; 81(4): 330-342.

8. Clark MA, Stein REK, Silver EJ, Khalid S, Fuloria M, Esteban-Cruciani NV. Carnitine deficiency in preterm infants: A national survey of knowledge and practices. J Neonatal Perinatal Med. 2017; 10(4): 381-386.

9. Baronio F, Righi B, Righetti F, Bettocchi I, Ortolano R, Faldella G et al. Carnitine longitudinal pattern in preterm infants <1800 g body weight: a case-control study. Pediatr Res. 2019; 86(5): 646-650.

10. Liu Q, Wu J, Shen W, Wei R, Jiang J, Liang J et al. Analysis of amino acids and acyl carnitine profiles in low birth weight, preterm, and small for gestational age neonates. J Matern Fetal Neonatal Med. 2017; 30(22): 2697-2704.

11. Vacha GM, Giorcelli G, Siliprandi N, Corsi M. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol. Am J Clin Nutr. 1983; 38(4): 532-540.

12. Laboratorios Grossman. Información para prescribir Cardispán® Solución Pediátrica al 10% y Solución Oral al 30%. 2016. México.

13. Rebouche CJ, Engel AG. Tissue distribution of carnitine biosynthetic enzymes in man. Biochim Pharmacol. 1987; 36(20): 3045-3049.

14. Almannai M, Alfadhel M, El-Hattab AW. Carnitine inborn errors of metabolism. Molecules. 2019; 24(18): 3251.

15. Rebouche CJ. Carnitine. In: Shils ME, Olson JA, Shike M, Ross AC, editors. Modern nutrition in health and disease. 9th ed. Baltimore: Lippincott Williams & Wilkins; 1999. pp. 505-512.

16. Montgomery R, Espector A. Bioquímica casos y texto. 6ª ed. España: Elsevier; 1999.

17. Schiff D, Chan G, Seccombe D, Hahn P. Plasma carnitine levels during intravenous feeding of the neonate. J Pediatr. 1979; 95(6): 1043-1046.

18. Sánchez-Pintos P, Pérez-Muñuzuri A, Cocho JÁ, Fernández-Lorenzo JR, Fraga JM, Couce ML. Evaluation of carnitine deficit in very low birth weight preterm newborns small for their gestational age. J Matern Fetal Neonatal Med. 2016; 29(6): 933-937.

19. Engel AG, Rebouche CJ. Carnitine metabolism and inborn errors. J Inherit Metab Dis. 1984; 7 Suppl 1: 38-43.

20. Schmidt-Sommerfeld E, Penn D, Wolf H. Carnitine blood concentrations and fat utilization in parenterally alimented premature newborn infants. J Pediatr. 1982; 100(2): 260-264.

21. Mitchell ME, Synder EA. Dietary carnitine effects on carnitine concentrations in urine and milk in lacting women. Am J Clin Nutr. 1991; 54(5): 814-820.

22. Usher R, McLean F. Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr. 1969; 74(6): 901-910.

23. MacDonald MG, Fletcher MA, Avery GB. Neonatología, fisiopatología y manejo del recién nacido. 5ª ed. Argentina: Editorial Médica Panamericana S.A.; 2001.

24. Bonner CM, DeBrie KL, Hug G, Landrigan E, Taylor BJ. Effects of parenteral L-carnitine supplementation on fat metabolism and nutrition in premature neonates. J Pediatr. 1995; 126(2): 287-292.

25. Coran AG, Drongowski R, Baker PJ. The metabolic effects of oral L-carnitine administration in infants receiving total parenteral nutrition with fat. J Pediatr Surg. 1985; 20(6): 758-764.

26. Curran JS, Williams PR, Kanarek KS, Novak M, Monkus EF. An evaluation of orally supplemented L-carnitine in premature infants receiving Intralipid 20%. Acta Chir Scand Suppl. 1983; 517: 157-164.